SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending due to a massive volume spike and price surge, triggering multiple trading halts, as community discussion focuses on its extremely low float and high insider ownership for a potential short squeeze. Many are comparing it to recent explosive SPACs, with speculative targets suggesting significant upside, fueled by talking points like a rumored "sex toy manufacturer" acquisition. The stock's momentum reflects its position as a key play in the current "SPAC mania" for micro-float tickers.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is rapidly trending due to a potent combination of its extremely low share float and a potential short squeeze, driving significant momentum. The recent announcement of a strategic manufacturing partnership, expected to boost production margins, further amplifies investor interest. The community is actively discussing strong buying defense and a "textbook" short squeeze play as the company continues to expand global adoption of its fingerprint drug screening technology.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending amid renewed optimism driven by China's extension of EV trade-in subsidies into 2026 and robust Q4 sales forecasts, including potential record December deliveries. The community is actively discussing strong operational performance and strategic advancements like battery swapping, with many bullish investors accumulating shares on expectations of profitability. However, some continue to voice concerns over persistent market manipulation impacting the stock's valuation despite positive developments.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics (CORT) is trending due to the FDA issuing a Complete Response Letter for its relacorilant drug, triggering significant market volatility. The community is sharply divided, with some investors calling for further decline and celebrating put option gains, while others view the sell-off as an overreaction. Many highlight the company's existing profitable drug and argue that the FDA's acknowledgment of positive trial data suggests a path forward, creating a potential dip-buying opportunity.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is trending following its recent FDA approval of NEREUS, the first new motion sickness treatment in over four decades, validating a significant pipeline asset. Community discussion highlights the drug's broader potential for GLP-1 induced nausea, fueling speculation of substantial upside, a potential short squeeze, and even a buyout, given the company's strong financial standing and additional upcoming regulatory catalysts.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings (ONDS) is trending due to recent autonomous system orders and the FCC's ban on foreign-made drones, which significantly boosts its role in the domestic market. The community is actively discussing a potential short squeeze and anticipating a significant price breakout, with many seeing dips as buying opportunities. This positions Ondas as a crucial player in the growing defense and critical infrastructure sectors for autonomous and counter-drone solutions.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after rival Corcept Therapeutics received an FDA Complete Response Letter for its Cushing's syndrome drug, effectively removing a near-term competitor for Xeris's Recorlev. The community is buzzing with bullish sentiment, emphasizing Recorlev's blockbuster potential and the significant undervaluation of XERS, further supported by advancing pipeline assets like XP-8121 and robust gross margins.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amidst a wave of strong bearish sentiment, largely attributed to sustained selling pressure, high short interest, and year-end tax loss harvesting. The community is actively discussing the recent FDA approval of Novo Nordisk's oral Wegovy pill, seeing a potential for partnership and a significant catalyst for HIMS's future growth in GLP-1 offerings, alongside its ongoing expansion in D2C lab testing and international markets. Despite current frustration, many long-term investors are using this dip as a buying opportunity, anticipating a strong reversal.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending following its CEO's strategic insights on CNBC and news of spinning off its cloud business into ChronoScale, a move seen by many as unlocking significant value and clarifying its pure-play AI data center infrastructure focus. The community is actively discussing sustained demand from hyperscalers and strong analyst confidence ahead of its upcoming earnings report, fueling bullish sentiment despite recent price volatility. This strategic realignment aims to capitalize on the booming AI infrastructure market with a clearer business model and substantial contracted revenue.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to the FDA's acceptance and priority review of its supplemental New Drug Application for AXS-05 in Alzheimer's disease agitation, with an action date anticipated in the near future. This significant regulatory milestone, combined with growing sales of its existing CNS therapies like Auvelity, has ignited immense optimism within the community, with many anticipating substantial long-term value and discussing breakthrough potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BIAF Stock Dips After Q3 Earnings Reflect Lower Sales and Wider Loss

bioAffinity's third-quarter 2025 performance shows lower sales and a wider loss as it pivots to focus on CyPath Lung and expands VA system adoption.

bioAffinity Technologies Reports Third Quarter 2025 Financial Results

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on providing noninvasive, accurate detection of early-stage lung cancer and other lung diseases, today reported...

bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage diagnostics including CyPath Lung, the Companys noninvasive test for lung cancer, today announced...

bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath Lung, the Companys commercially available test for early-stage...

bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements

WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules WallachBeth Capital Announces The...

bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced it has closed the...

WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules WallachBeth Capital Announces...

bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has entered...

Shares of bioAffinity Technologies (BIAF) soared 79% on Friday after the company released three additional case studies, including one in which the use of its CyPath Lung test led to the detection of lung cancer at an early, possibly curable stage.The company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250926999689/en/bioAffinity-Technologies-Adds-to-Growing-Number-of-Case-Studies-Demonstrating-Clinical-Value-of-CyPath-Lung">stated</a> that two potentially risky invasive procedures were avoided for patients facing difficult healthcare choices by using the test.CyPath Lung is a non-invasive test designed to enhance the early detection of lung cancer in patients at high risk for the disease. It uses advanced flow cytometry and artificial intelligence (AI) to identify cell populations in a patient’s sputum that indicate malignancy. In clinical studies, it was demonstrated that CyPath Lung had a sensitivity of 92%, specificity of 87%, and an accuracy of 88%.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BIAF">BIAF stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.BioAffinity stated that the three new cases were provided by a Texas pulmonologist who has been using the test for over a year. While early-stage lung cancer was diagnosed in 68-year-old Samuel with the help of the test, David avoided an unnecessary biopsy after the test came out negative. Lisa, with a previous diagnosis of lung cancer, proceeded with radiation therapy after a positive CyPath Lung result without performing a biopsy, as she might not have been healthy enough for the procedure.“We believe CyPath Lung can be a transformative tool in the lung cancer diagnostic pathway, especially when imaging results are inconclusive. A positive CyPath Lung result can lead to earlier diagnosis and treatment, and a negative result can spare patients from unnecessary invasive procedures,” Chief Medical Officer Gordon Downie said.BIAF stock is down 78% this year and by 90% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pharmaceutical-tariffs-a-light-at-the-end-of-the-trump-tunnel-for-big-pharma-says-jefferies/chDViCCR3e4">Pharmaceutical Tariffs ‘A Light At The End Of The Trump Tunnel’ For Big Pharma, Says Jefferies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

bioAffinity Technologies Stock Surged A Whopping 79% Today – Here’s An Important Update

The company reported that the use of its CyPath Lung test enabled the detection of lung cancer at an early stage.

Equity

The company reported that the use of its CyPath Lung test enabled the detection of lung cancer at an early stage.


bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.

BIAF
BioAffinity Technologies Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BIAF News

BIAFBioAffinity Technologies Inc